Targeting oral epithelial dysplasia with antigen-specific immunity
Date
2022-12-01
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Abdulaziz Alboushi
Abstract
This project aimed to establish a novel approach that these two antigens may become potential targets in OED and/or biomarkers for malignant transformation. With the broad expression of MAGED4B and FJX1 antigens in head and neck cancer, these two antigens would be potential targets in OED. MAGED4B and FJX1 antigens are expressed in OED and HNSCC with immune response against these antigens. MAGED4B and FJX1 antigens expression is prospective to be high in progressed OED. Also, the more the grading the more the expression and in the same case the immune response.
Description
Therapeutic vaccines targeting tumour antigens is considered a promising to activate the immune system in favor of eliminating cancer as research suggest. Considering DNA vaccine as a trusted therapeutic vaccine, patients with head and neck cancer could be benefited from such a developed therapeutic approach. This may be accomplished by vaccinating patients with oral epithelial dysplasia (OED) before transformation to oral squamous cell carcinoma (OSCC) therefore prevent head and neck cancer progression. Considering the broad expression of MAGED4B and FJX1 antigens in head and neck cancer, the hypothesis that will be tested is that these two antigens would be potential targets in OED as well. To develop this strategy, the expression of these antigens should undergo evaluation along with testing their immune visibility in OED patients. However, this is a novel approach, as the right vaccine target has not been identified yet. Therefore, the purpose of this study is to determine suitability of MAGED4B and FJX1 as candidates to target OED.
Keywords
Immunotherapy, Cancer vaccine, Head and neck cancer, Oral epithelial dysplasia